Will be us lot!!
Hate to say it but
The only explanation for the downward spiral must be someone privy to inside information selling why else?
More than £70k in the red now starting to get a little pee’ed off!!!
Come on bod pull your fingers out and do something anything must be better than nothing!!!
GLA!!
Agree that it’s crazy they’re currently valued higher than NFX.
A little bit of history on them though. They’re on their 3rd or 4th consolidation so lths there are massively in the red and most will need £2/3 just to break even. They don’t seem to have any interest in their products they have spent their investors money on. The market work on mysterious ways lol.
GLA!!
Let’s hope we don’t end up like them
“All pure speculation but given the uncertainty of our position and the fact that we won't have a CEO soon”
Correct pure speculation(I would say utter nonsense) uncertainty?? You’ll have to elaborate on that one as far as I’m aware we’re awaiting read outs on the 2 other drugs in the pipeline if positive both could generate licensing opportunities!! I’m sure it’s been addressed by the company that after data release they will look for a replacement ceo??
So other than post utter nonsense all day every day what is your agenda??
Soup many would think from your sudden change in stance maybe you’ve sold and now looking for a cheaper entry!!
“Secret backers” lol!!! Have a break think it’s all getting to your head!!!
When people buy the shares it will go up when they sell (like yesterday) it will continue to go down
Why do you feel the need to know this information other than bash the price even more what benefit would it make giving you the information you are crying out to know? What/why would you do with this information other than twist it into a negative narrative??
It’s not uncommon for companies to disclose amounts due to confidentiality agreements and competitive reasons.
All you lot would do is moan about the numbers anyway so why bother giving them to you?
Perplexed as to how ffx is know trying to negatively put down NXP002 although it has nothing to do with NXP001
The company now has an income stream it’s positive get a life you old moaning farts!!!
Next news NXP002 and NXP004 updates wait patiently or feck off!!!
“Traders”. ??
You are posting about yourself!
“Traders that thought the Ox deal would see buyers flocking in. Little research imo”.
Earlier post
Usual "undisclosed " lol. Investors obviously once again no right to know. Therefore probably nothing to shout about. And the ball very much on the Ox court.
Traded those I bought at 1.3p. Made a little, but was hoping for more.
This was never going to be a game changer for nfx, and as I said earlier, a deal just for the sake of it would be easily recognised as such by the markets.
And moaning about why it’s not going higher!!
“Traders”. ??
You are posting about yourself you muppet
“Traders that thought the Ox deal would see buyers flocking in. Little research imo”.
Earlier post
“Usual "undisclosed " lol. Investors obviously once again no right to know. Therefore probably nothing to shout about. And the ball very much on the Ox court.
Traded those I bought at 1.3p. Made a little, but was hoping for more.
This was never going to be a game changer for nfx, and as I said earlier, a deal just for the sake of it would be easily recognised as such by the markets.”
Conclusion
****** !!
It’s not nfx but it’s a preclinical study that shows inhalation is better than intravenously injections in the vein
In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial.
These promising findings, which support Pieris’ plans to launch a Phase 1 trial of PRS-220 next year, were presented in a poster titled, “Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF,” at the European Respiratory Society International Congress 2021, held virtually Sept. 5–8.
“PRS-220 exemplifies our respiratory strategy of advancing programs addressing clinically-validated targets where a local approach may provide significant benefit to patients,” Shane Olwill, PhD, Pieris’ chief development officer, said in a press release.
Connective tissue growth factor (CTGF) is a protein found at higher-than-normal levels in the lung tissue of people with IPF. It contributes to the progressive and excessive tissue scarring (fibrosis) characteristic of the disease. As such, therapeutic approaches suppressing CTGF are thought to have the potential to prevent the activation of downstream pro-inflammatory and pro-fibrotic factors, thereby slowing or halting IPF progression.
In agreement, pamrevlumab — FibroGen’s experimental anti-CTGF antibody that is delivered directly into the bloodstream — was shown to safely and effectively slow lung function decline in IPF patients in a Phase 2 trial (NCT01890265).
https://pulmonaryfibrosisnews.com/2021/09/08/inhaled-prs-220-superior-into-the-vein-pamrevlumab-idiopathic-pulmonary-fibrosis-ipf-preclinical-data/
Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021
Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021.
A patent filed in 2020 may be granted in 2022.
Licensing deal under negotiation with Oxilio. A licensing deal is being finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment. Licensing agreement could be announced anytime soon.
Indicative value NXP002
. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m.
Fully funded
Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022
Question 7
Anne – are you more or less confident in the Company’s prospects than when you joined?
The Company is in a better position than when I joined – it is on a stronger financial footing with sufficient funds to do the planned studies with a runway beyond that. In addition, operational activities have been optimized and costs minimized, such that funds can be prioritized towards generating data on the portfolio assets to add to their value. The R&D work is progressing well for both NXP002 and NXP004 and I remain confident that these assets bring good opportunities
“ The R&D work is progressing well for both NXP002 and NXP004 and I remain confident that these assets bring good opportunities”
Fully funded and research progressing well!!!
GLA!!
The same bunch of idiots that spent most of last week in particular Friday crying like baby’s screaming for the release of the Q and A now saying it’s not good enough! You people are pathetic! Pretty predictable really
Average down or feck off you miserable old sods!!!
Q n a
https://nuformix.com/app/uploads/2021/08/NFX-AGM-2021-QA-27.08.21_Final.pdf
“ Clearly once further information is available regarding the way forward for the other programmes and alliances, we would look to revise our overall valuation assumptions.”
Conclusion
“NFX operates a relatively low risk and cost development model in which it is developing innovative forms of older drugs focused on high value commercial markets. In our view, a successful development of a preclinical package for the lead programme in IPF can be a differentiated and attractive target for licensing or acquisition by larger pharma players, judging by deal flow, market metrics and unmet need.”
. If it strikes a deal or deals at the preclinical stage then the return is likely to be a global deal package of around $360-450m, including upfront and milestones, plus mid to high single digit royalties on sales, based on recent market precedent, while there is potential for total deal value (upfront and milestones) to increase and royalties to rise to the mid-teens if a deal comes after NFX completes Phase I work on NXP002.
Beyond IPF, next steps in Fibrosis and Oncology
NFX has the option to investigate the scientific rationale for treating other diseases with NXP002 candidates for the broader fibrotic and oncology indications provided that the proof of concept is established This includes alleviating hyper-inflammation of the lungs in COVID-19 patients targeting the NLRP3 inflammasone, a key pathway in many inflammatory lung conditions such as Acute Respiratory Distress Syndrome (ARDS) and a
21
NUFORMIX PLC ( NFX.L)| 10 March 2021
Allenby Capital
well-documented mechanism of tranilast7. The preclinical plan, which hinges on the feasibility and activity of NXP002 as delivered by the inhaled route, will also form a foundation for future studies in other lung diseases. There will be no additional expenditure allocated to other indications at the preclinical stage by NFX as firstly NFX is focussed on IPF as the disease target and secondly, several of the evaluation steps, including the confirming feasibility of administration via nebuliser and inhalation safety, would be the same for any lung disease.
I’m sure collectively many would be against 2/3p!!
It’s a strange old game sentiment at all time low along with share price you would think now is the best time to buy!!! it was a great buy at 8/9/10/11/12/13p but at 1.4p in the run up to important data due 2 fold and also now 2 patents granted for lead drug candidate all the stale bulls are sulking ?
Strange mentality but imo now is the time to be loading up guess each to their own I suppose
GLA!!!